TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17358096
Drug: Rectally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectally administered oxcarbazepine suspension (300 mg and 450 mg doses)
Study: 7988364
Drug: Hydrochlorothiazide (HCT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT; <= 25 mg daily)
Study: 3141491
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day parenteral folinic acid
Study: 3141491
Drug: 50 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/week parenteral folinic acid
Study: 19364291
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg of MPH
Study: 10628766
Drug: Prednisone withdrawal
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone withdrawal (tapered over 8 weeks to 0 mg/day)
Study: 10628766
Drug: Prednisone maintenance
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone maintenance (10 mg/day)
Study: 7707112
Drug: High-dose experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose experimental therapy
Study: 7707112
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment or experimental agent
Study: 7707112
Drug: Different therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different therapies for a 6-month addition to life expectancy
Study: 7707112
Drug: Randomization to
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization to a clinical trial comparing high-dose with standard chemotherapy
Study: 2390879
Drug: Inosine, 50‐90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine, 50‐90 mg/kg daily in divided doses
Study: 24004292
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (200,000 IU for 2 months, then 100,000 IU monthly for 18 months)
Study: 12138146
Drug: gentamicin/citrate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: gentamicin/citrate (40 mg/ml and 3.13% citrate; ratio 2:1)
Study: 12138146
Drug: heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin (5000 U/ml)
Study: 9570264
Drug: Hypotonic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic solution (160 mOsmol/kg)
Study: 16758849
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution
Study: 8214753
Drug: Edrophonium (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.1, 0.2, 0.4, or 1 mg/kg)
Study: 8214753
Drug: Neostigmine (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg)
Study: 2568767
Drug: Edrophonium (0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.44 +/- 0.11 mg/kg with atracurium and 0.46 +/- 0.12 mg/kg with vecuronium)
Study: 25558975
Drug: Motor control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor control therapy
Study: 19779321
Drug: Lersivirine (UK-453,061)
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine (UK-453,061) 100 mg twice daily
Study: 19779321
Drug: Lersivirine (UK-453,061)
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine (UK-453,061) 500 mg twice daily
Study: 19779321
Drug: Lersivirine (UK-453,061)
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine (UK-453,061) 750 mg once daily
Study: 15900307
Drug: Soy supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplement (30 g soy protein, 9 g cotyledon fibre, 100 mg isoflavones)
Study: 15900307
Drug: Soy supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplement
Study: 12802453
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy with larifan, ridostin, and viferon for 1 month
Study: 9796889
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg orally twice daily
Study: 23477506
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement for 8 weeks
Study: 15163340
Drug: T4/T3 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4/T3 combination therapy
Study: 20466363
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg conjugated estrogens orally for 7 days
Study: 20466363
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g conjugated estrogens vaginally for 7 days
Study: 9123711
Drug: High-dose yohimbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose yohimbine hydrochloride (36 mg per day orally)
Study: 1971641
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g)
Study: 29413356
Drug: 4g/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g/day of prescription omega‐3 fatty acids (P‐OM3) for 16 weeks
Study: 27095306
Drug: Sonidegib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib (200 mg or 800 mg doses)
Study: 22281018
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of anastrozole (1 mg)
Study: 22281018
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of anastrozole (1 mg)
Study: 20498181
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg THC twice daily
Study: 18365856
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (1 mg estradiol + 0.125 mg trimegestone)
Study: 18365856
Drug: Nasal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal hormone replacement therapy (150 or 300 microg estradiol + 200 mg micronized progesterone)
Study: 9536660
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg) in three divided doses
Study: 9536660
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (400 mg)
Study: 10657288
Drug: Carbamazepine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (200 mg)
Study: 3338255
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between strength and amount of walking (daily steps)
Study: 28915900
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus vinorelbine (standard treatment)
Study: 26403745
Drug: SMOF (lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMOF (lipid emulsion formulation containing soybean oil, medium chain triglycerides, olive oil, and fish oil)
Study: 23497590
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral glucocorticoid dosing
Study: 23497590
Drug: Reduced oral
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced oral glucocorticoid dosing
Study: 18202589
Drug: Pueraria mirifica
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica (20, 30, or 50 mg once daily for 24 weeks)
Study: 18202589
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules once daily for 24 weeks)
Study: 16279282
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment (unopposed conjugated estrogens (CEE) 0.625 mg/day if without a uterus; CEE combined with medroxyprogesterone acetate (MPA) 2.5 mg/day otherwise)
Study: 7942668
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with omeprazole 40 mg, amoxicillin, and metronidazole
Study: 27255923
Drug: Existing program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing program with monthly growth monitoring and nutritional/hygiene education (T0)
Study: 17805230
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (26+/‐5 g protein containing 44+/‐8 mg isoflavones per day)
Study: 17805230
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein isolate (26+/‐5 g protein per day)
Study: 20132103
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg
Study: 14739037
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin 80 mg/m2 on day 1; vindesine 3 mg/m2 on days 1 and 8: x3 courses)
Study: 25936321
Drug: Atorvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin monotherapy
Study: 25577723
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus ezetimibe (10 mg) daily
Study: 24079283
Drug: Colesevelam (3750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3750 mg/d) with niacin titration
Study: 24079283
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with niacin titration
Study: 21133824
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg allopurinol daily for 12 weeks
Study: 3057844
Drug: Propafenone 675
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 675 mg/day
Study: 7135
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg
Study: 6093960
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg
Study: 25332478
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei DG (24 billion viable cells daily for 4 weeks)
Study: 22054033
Drug: Super Poligrip®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Poligrip® Free (cream)
Study: 22054033
Drug: Cream adhesives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream adhesives
Study: 11837527
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy interventions
Study: 9651905
Drug: HRT-group: Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT-group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate + vitamin D3 300 IU/day + calcium lactate 500 mg/day (n = 31)
Study: 9651905
Drug: non-HRT-group: Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-HRT-group: Calcium lactate 500 mg/day + vitamin D3 300 IU/day (n = 33)
Study: 7898842
Drug: Intravaginal 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 2.5 mg of PGE2 gel every hour
Study: 7898842
Drug: Intravaginal 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 2.5 mg of PGE2 gel every 6 hours
Study: 2655717
Drug: Timiperone 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timiperone 1 mg, 3 mg, 6 mg
Study: 2655717
Drug: Sulpiride 100
Normalized name: sulpiride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 100 mg, 300 mg, 600 mg
Study: 792642
Drug: Fenoterol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (1 mg)
Study: 9510443
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (recombinant GH 0.1 IU/kg/day)
Study: 3124593
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat intake (450 mg.kg‐1.d‐1) at 60 kcal.kg‐1.d‐1
Study: 3124593
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat intake (450 mg.kg‐1.d‐1) at 60 kcal.kg‐1.d‐1
Study: 24755123
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg with 500 mg, 850 mg, or 1,000 mg metformin (FDC)
Study: 24755123
Drug: Individual tablets
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual tablets of linagliptin and metformin (FP)
Study: 17619862
Drug: Information emphasizing
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information emphasizing patch benefits (n = 25)
Study: 17619862
Drug: Nicotine-dose instructions
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-dose instructions (n = 25)
Study: 12668365
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg/day
Study: 14628989
Drug: Paroxetine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 60 mg/day
Study: 10023508
Drug: L-tryptophan 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan 6 g per day
Study: 373085
Drug: phenylbutazone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylbutazone (100 mg 3 times daily)
Study: 7113925
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily safety lecture group (S)
Study: 28278010
Drug: Valerian 530
Normalized name: valerian 530 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian 530 mg capsule twice per day for two months
Study: 28278010
Drug: Placebo 530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 530 mg capsule (starch)
Study: 26915963
Drug: Need supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Need supportive (NS) SMS sent twice weekly for 10 weeks
Study: 24914136
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (transfusions/chelation)
Study: 21761190
Drug: LipoNasal n
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipoNasal n nasal spray (LNM)
Study: 21761190
Drug: LipoNasal n
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipoNasal n nasal spray and Tears Again eye spray combination therapy (LTC)
Study: 21761190
Drug: Standard cromoglycate
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard cromoglycate combination therapy (CGC)
Study: 16002030
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg transdermal nicotine patch
Study: 23868855
Drug: Trivair Nasal
Normalized name: triamcinolone acetonide Prefilled Syringe [Trivaris]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivair Nasal Deposition System delivering anhydrous lactose particles (5 μm and 50 μm at doses of 12.5 mg and 25 mg)
Study: 10219066
Drug: D-chiro-inositol (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-chiro-inositol (1200 mg once daily for 6-8 weeks)
Study: 9661119
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg rhGH
Study: 9661119
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg rhGH
Study: 7191647
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% in 8.25% dextrose, 12 mg
Study: 7191647
Drug: Tetracaine, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine, 12 mg
Study: 7191647
Drug: Epinephrine added
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine added to local anesthetic solution
Study: 30359438
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g sucrose (control)
Study: 22856247
Drug: Control biscuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control biscuits (100 g providing 497 kcal and 11.36 g of protein)
Study: 16008116
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg EGCG
Study: 12655619
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral therapy (CBT)
Study: 12655619
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT)
Study: 11034937
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg testosterone daily by transdermal patch
Study: 2054265
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (850 mg)
Study: 27077673
Drug: PEGylated‐interferonα2b (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGylated‐interferonα2b (1.5 μg/kg/week) + ribavirin (800‐1400 mg/day) + boceprevir (800 mg TID)
Study: 22909899
Drug: Oseltamivir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir monotherapy (O)
Study: 18076252
Drug: Sports Gel
Normalized name: Snow & sun sports gel
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports Gel
Study: 18303227
Drug: Deep sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sclerectomy with low-dosage mitomycin C (DSMMC)
Study: 18303227
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with low-dosage mitomycin C (TPMMC)
Study: 7547820
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg temazepam elixir
Study: 8248349
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (10 mg/kg)
Study: 23527884
Drug: Open-label therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label therapy after optimization
Study: 12756640
Drug: Systemic cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic cephalexin and ethyl lactate shampoo therapy
Study: 9510449
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment for phenylketonuria (PKU)
Study: 29136336
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg single oral dose
Study: 26871201
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg starch (placebo)
Study: 22964926
Drug: Budesonide-formoterol combination
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol combination (400 µg budesonide and 12 µg formoterol)
Study: 22964926
Drug: Budesonide alone
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide alone (400 µg)
Study: 8810809
Drug: 13C-urea (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C-urea (50 mg)
Study: 8810809
Drug: 13C-urea (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C-urea (100 mg)
Study: 1191783
Drug: Scheme I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme I: 100 rad 3 times a day, 5 days a week, total tumor dose of 8,400 rad, with 2 weeks of rest in the middle of treatment.
Study: 1191783
Drug: Scheme II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme II: 200 rad once a day, 5 days a week, total tumor dose of 6,400 rad, with 2 weeks of rest in the middle of treatment.
Study: 12933402
Drug: Ephedrine 0.1
Normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.1 mg/kg
Study: 322547
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/ml) administered by microdrip at an average rate of 10 ml/min
Study: 322547
Drug: Innovar (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovar (0.1 ml/ml) administered by microdrip at an average rate of 10 ml/min
Study: 17192165
Drug: Allopurinol (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (standard therapy)
Study: 16380617
Drug: Atomoxetine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5 to 1.5 mg/kg/day)
Study: 8604540
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (local hypotensive therapy only)
Study: 913121
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg flurbiprofen daily
Study: 334476
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg phenylbutazone daily
Study: 23545863
Drug: Levosimendan 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.1 μg/kg/min
Study: 3552679
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with verapamil (120 mg daily)
Study: 3552679
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose digoxin
Study: 31732098
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus Ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk)
Study: 31732098
Drug: Sunitinib (50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg once daily, 4 wk on, 2 wk off)
Study: 27053382
Drug: extruded FePP‐fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: extruded FePP‐fortified rice with CA/TSC solution added after cooking (CA/TSC solution)
Study: 27053382
Drug: nonextruded rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonextruded rice fortified with a FeSO4 solution added after cooking (reference)
Study: 10443077
Drug: Bilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ECT and flupenthixol (12‐24 mg/d)
Study: 7589058
Drug: Propranolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol with ascorbic acid (2 g)
Study: 2148876
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Study: 24756009
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/day)
Study: 22823594
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg slow release taken orally twice daily for 2.5 days